XXXX therapy in symptomatic, sustained refractory @entity4710 .

@entity1 @entity2643 @entity1165 @entity73 @entity1163 @entity591 @entity955 @entity1296 @entity1540 @entity4710 @entity943
@entity2643 was utilized in 70 @entity1 with symptomatic, sustained refractory @entity591 . Of these, 29 had @entity943 (20 recurrent @entity955 and nine sustained @entity4710 ). Control was achieved in eight with @entity4710 and in 16 with @entity955 . Recurrence has been prevented in these 24 @entity1 (83%) during an average follow-up of 13.4 months. An additional 41 @entity1 had recurrent @entity1165 . In 19 with symptoms consisting of @entity1296 without @entity1163 or clinically apparent hemodynamic compromise, treatment was limited to @entity2643 . Of these, 14 responded (74%) and have been free of @entity943 during an average follow-up of 13 months. In 22 who had experienced either @entity1163 or life-threatening @entity73 , @entity2643 was added to those agents which had only partially suppressed advanced grades of @entity1540 . Fourteen of these @entity1 (64%) have remained free pf recurrent @entity943 during an average follow-up of 12 months. After drug loading, maintenance therapy consisted of a daily dose ranging from 200 to 600 mg. Only mild side effects have been encountered in the 17 @entity1 (23%) with any untoward responses. This experience confirms that oral @entity2643 is an effective and safely applied agent against recurrent refractory @entity4710 and sustained intractable @entity1165 with moderate symptoms. While also efficacious in refractory sustained life-threatening @entity1165 , usage of the agent is often difficult in this condition owing in part to insufficient information concerning @entity2643 pharmacokinetics.
